$2.47 Billion is the total value of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 109 reported holdings in Q4 2015. The portfolio turnover from Q3 2015 to Q4 2015 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| FLML | FLAMEL TECHNOLOGIES SAsponsored adr | $49,729,000 | -25.1% | 4,072,809 | 0.0% | 2.02% | -21.6% | |
| HEALTHWAYS INCnote 1.500% 7/0 | $49,087,000 | +2.5% | 51,925,000 | 0.0% | 1.99% | +7.4% | ||
| ARRAY BIOPHARMA INCnote 3.000% 6/0 | $42,292,000 | -3.6% | 45,000,000 | 0.0% | 1.71% | +1.0% | ||
| HEARTWARE INTL INCnote 3.500%12/1 | $37,364,000 | -0.9% | 39,226,000 | 0.0% | 1.51% | +3.8% | ||
| TEVA | TEVA PHARMACEUTICAL INDS LTDcall | $36,102,000 | +16.3% | 550,000 | 0.0% | 1.46% | +21.8% | |
| ENDOLOGIX INCnote 2.250%12/1 | $34,602,000 | -6.2% | 40,941,000 | 0.0% | 1.40% | -1.8% | ||
| EHTH | EHEALTH INC | $32,581,000 | -22.1% | 3,264,588 | 0.0% | 1.32% | -18.4% | |
| HWAY | HEALTHWAYS INC | $31,725,000 | +15.7% | 2,465,042 | 0.0% | 1.29% | +21.3% | |
| ACCURAY INCnote 3.750% 8/0 | $30,875,000 | +0.1% | 30,511,000 | 0.0% | 1.25% | +4.9% | ||
| NVLS | NIVALIS THERAPEUTICS INC | $28,889,000 | -40.3% | 3,732,412 | 0.0% | 1.17% | -37.5% | |
| KMPH | KEMPHARM INC | $28,211,000 | +2.5% | 1,420,497 | 0.0% | 1.14% | +7.3% | |
| AERI | AERIE PHARMACEUTICALS INC | $19,672,000 | +37.3% | 807,875 | 0.0% | 0.80% | +43.9% | |
| PRTO | PROTEON THERAPEUTICS INC | $19,625,000 | +11.5% | 1,265,343 | 0.0% | 0.80% | +16.7% | |
| ACHN | ACHILLION PHARMACEUTICALS IN | $17,987,000 | +56.2% | 1,667,000 | 0.0% | 0.73% | +63.5% | |
| AXGN | AXOGEN INC | $16,907,000 | +21.4% | 3,381,439 | 0.0% | 0.68% | +27.1% | |
| DBVT | DBV TECHNOLOGIES S Asponsored adr | $16,770,000 | +2.0% | 461,869 | 0.0% | 0.68% | +6.9% | |
| AKTX | AKARI THERAPEUTICS PLCsponsored adr | $16,685,000 | -39.6% | 1,150,700 | 0.0% | 0.68% | -36.7% | |
| NSTG | NANOSTRING TECHNOLOGIES INC | $12,954,000 | -8.1% | 880,622 | 0.0% | 0.52% | -3.7% | |
| TNXP | TONIX PHARMACEUTICALS HLDG C | $10,090,000 | +45.0% | 1,315,551 | 0.0% | 0.41% | +52.0% | |
| ESSA PHARMA INC | $8,499,000 | -26.6% | 1,859,282 | 0.0% | 0.34% | -23.2% | ||
| FOMX | FOAMIX PHARMACEUTICALS LTD | $7,696,000 | +10.6% | 948,934 | 0.0% | 0.31% | +16.0% | |
| RIGL | RIGEL PHARMACEUTICALS INC | $7,266,000 | +22.7% | 2,397,855 | 0.0% | 0.29% | +28.4% | |
| NEOS | NEOS THERAPEUTICS INC | $6,563,000 | -31.8% | 458,332 | 0.0% | 0.27% | -28.7% | |
| OXFD | OXFORD IMMUNOTEC GLOBAL PLC | $5,976,000 | -14.8% | 519,670 | 0.0% | 0.24% | -10.7% | |
| CASM | CAS MED SYS INC | $5,664,000 | +41.6% | 3,200,000 | 0.0% | 0.23% | +48.4% | |
| EGLTQ | EGALET CORP | $5,258,000 | -16.4% | 477,123 | 0.0% | 0.21% | -12.3% | |
| JAZZ INVESTMENTS I LTDnote 1.875% 8/1 | $5,223,000 | +2.5% | 5,000,000 | 0.0% | 0.21% | +7.6% | ||
| ALDX | ALDEYRA THERAPEUTICS INC | $4,682,000 | +16.3% | 690,538 | 0.0% | 0.19% | +21.8% | |
| TCON | TRACON PHARMACEUTICALS INC | $4,481,000 | -5.4% | 485,000 | 0.0% | 0.18% | -0.5% | |
| TRIB | TRINITY BIOTECH PLCspon adr new | $2,893,000 | +2.8% | 246,000 | 0.0% | 0.12% | +7.3% | |
| ACUR | ACURA PHARMACEUTICALS INC | $2,564,000 | +6.4% | 1,025,641 | 0.0% | 0.10% | +11.8% | |
| TRILLIUM THERAPEUTICS INC | $2,173,000 | -3.2% | 172,307 | 0.0% | 0.09% | +1.1% | ||
| ATEC | ALPHATEC HOLDINGS INC | $1,495,000 | -9.1% | 4,982,738 | 0.0% | 0.06% | -4.7% | |
| CDNA | CAREDX INC | $1,466,000 | +53.5% | 229,000 | 0.0% | 0.06% | +59.5% | |
| BVX | BOVIE MEDICAL CORP | $1,445,000 | +7.7% | 688,229 | 0.0% | 0.06% | +13.5% | |
| PTN | PALATIN TECHNOLOGIES INC | $1,328,000 | -18.0% | 2,000,000 | 0.0% | 0.05% | -14.3% | |
| CORSICANTO LTDnote 3.500% 1/1 | $901,000 | -1.7% | 1,000,000 | 0.0% | 0.04% | +5.7% | ||
| POZN | POZEN INC | $305,000 | +17.3% | 44,583 | 0.0% | 0.01% | +20.0% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AERIE PHARMACEUTICALS INC | 36 | Q3 2022 | 3.6% |
| CENTENE CORP DEL | 30 | Q3 2023 | 3.0% |
| BIOCRYST PHARMACEUTICALS INC | 29 | Q3 2023 | 2.2% |
| MOLINA HEALTHCARE INC | 26 | Q3 2022 | 1.7% |
| EHEALTH INC | 25 | Q3 2020 | 2.0% |
| INTERCEPT PHARMACEUTICALS IN | 24 | Q1 2023 | 2.2% |
| MYLAN NV | 23 | Q3 2020 | 6.2% |
| PORTOLA PHARMACEUTICALS INC | 23 | Q1 2019 | 6.0% |
| BROOKDALE SR LIVING INC | 23 | Q3 2023 | 2.2% |
| ALIMERA SCIENCES INC | 23 | Q3 2019 | 0.8% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| DA32 Life Science Tech Acquisition Corp. | August 01, 2023 | 5,145,000 | 91.1% |
| CareMax, Inc. | March 13, 2023 | 18,691,423 | 16.4% |
| CareMax, Inc. | June 02, 2022 | 18,691,423 | 20.7% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 3 | 2024-03-19 |
| 4 | 2024-03-19 |
| 4 | 2024-03-12 |
| 3 | 2024-03-08 |
| 4 | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-08 |
| 3 | 2024-02-01 |
| 4 | 2023-11-21 |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.